CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Viral Disinfectant Efficacy Studies: Key Guiding Factors And Design Elements

  Achieving compliance and safety through Disinfectant Efficacy Studies (DES) is about adhering to regulations and committing to high standards of safety and quality of manufacturing operations.

• Nucleic Acid-LNP Ultrafiltration And Diafiltration

  Downstream filtration can make or break LNPs at scale. See how membrane format, loading, and shear affect recovery and stability — and how alternative TFF lowers scale‑up risk.

• A Paradigm Shift From Glass Benchtop Bioreactors

  Learn how a bench-scale single-use bioreactor offers process development advantages over traditional glass systems, including higher efficiency, increased productivity, and enhanced sustainability.

• Consistent Improvement In CHO-K1 GS Performance With Efficient-Pro Feed 3 And Efficient-Pro Feed Enhancer

  Optimize your CHO-K1 GS cell line with advanced chemically defined, animal origin-free feeds. Achieve higher titers and reliable product quality.

• ADC Development Grows More Complex — SPR Insights Bring Clarity

  Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.

• AAV Capsid Analysis With Single Particle Mass Photometry

  Accurate AAV capsid ratios are critical to gene therapy efficacy. See how mass photometry delivers faster, lower-cost E/F analysis with single-particle resolution.

• Maintain Control Of Pharmaceutical Water Systems

  Early TOC excursions often reveal hidden risks in water systems. Capturing samples at the moment of deviation helps teams confirm root causes faster, reduce uncertainty, and maintain control.

• Enhanced Flow Kit Performance With Leak And PUPSIT Testing

  Sterile drug filtration demands rigorous integrity testing to prevent contamination. Learn how PUPSIT and in situ leak testing strengthen compliance with EU GMP Annex 1 and ensure reliable manufacturing.

• Efficient Late-Stage Development Of Biologics

  Reducing biologics manufacturing costs requires strategic late-stage process development, yield optimization, scale-up, and raw material substitution—all while maintaining product quality and regulatory compliance.

• Automated Fill And Finish For Cell Therapy

  Automated fill-finish systems protect sensitive cell therapies using low-shear handling to maintain dose uniformity, cell viability, and process consistency across every batch.